Heterocyclic compounds

Abstract: Aryl ureas and carbamic acid derivatives of formula A-NHCW-Y-B and pharmaceutically acceptable salts thereof wherein A is a specified aromatic radical including 3,5-dichlorophenyl W is O or S Y is NH or S and B is a specified saturated azacyclic ring, eg tropan-3-yl or quinuclidin-3-yl, possess 5-HT₃-antagonistic activity and are, for example, useful in treatment of migraine, emesis, anxiety, gastro-intestinal disorders and as anti-psychotics.

Description: This invention relates to heterocyclic compounds. In particular the invention relates to novel aryl ureas or carbamic acid derivatives, and the corresponding thio analogues, to processes for their preparation, to their use and to pharmaceutical compositions containing them. The novel compounds of the invention are useful as antagonists of specific 5-hydroxytryptamine (5-HT) receptors as explained hereinbelow. Certain related aryl ureas and carbamic acid derivatives are disclosed in European Patent Applications 235878 and 255297. In particular, EP-235878 discloses substituted phenyl urea and carbamic acid derivatives in which the ortho position contains a moiety capable of hydrogen bonding to the NH group of the urea or carbamic acid side chain. EP-158265 discloses benzamide and anilide derivatives having 5-HT antagonist activity. The present application is a divisional of European Patent Application No 88311802.8. The novel heterocyclic compounds of the present invention are those of the general formula and the pharmaceutically acceptable acid addition salts thereof. In this formula W represents oxygen or sulphur, Y represents NH or O, and B represents a saturated azacyclic ring of the formula where n is 2,3 or 4 and R³ is hydrogen, or (lower)alkyl, or or the N-oxide thereof or where m is 1, 2 or 3 and R³ has the meaning given above or where p is 0, 1 or 2 or where R⁴ and R⁵ are each hydrogen or lower alkyl. The term "lower" as used herein means that the radical referred to contains up to 6 carbon atoms. The radical preferably contains up to 4 carbon atoms. For example, a lower alkyl group may be straight chain or branched and may be methyl, ethyl, propyl or butyl. In the radical B of formula (II), preferably n is 2 and R³ is lower-alkyl, preferably methyl. The radical in which n is 2 and R³ is methyl is known as tropan-3-yl, otherwise 8-methyl-8-azabicyclo[3.2.1]octan-3-yl. The radical of formula (III) is known as quinuclidinyl, otherwise 1-azabicyclo[2.2.2]octan-3-yl. In the radical of formula (IV), preferably m is 2, and R³ is preferably C₁₋₄-alkyl, particularly methyl. In the radical of formula (V), p is preferably 1. The compounds of the invention may contain one or more asymmetric carbon atoms so that the compounds can exist in different stereoisomeric forms. The compounds can, for example, exist as racemates or optically active forms. The optically active forms can be obtained by resolution of the racemates or by using an optically active form of the starting material in the processes described hereinafter. Furthermore radicals such as those of formulae (II) and (IV) can exist in two different configurations corresponding to the endo configuration as in tropine and the exo configuration as in pseudotropine. The endo configuration is preferred. The compounds of the invention are aryl ureas as carbamic acid derivatives (or their corresponding thio analogues) and may be prepared by methods known for the preparations of urea and carbamic acid derivatives (and thio analogues). A first general process for preparing the compounds of the invention comprises reacting an isocyanate or isothiocyanate of formula (VII) (where W is as defined above) with an amine or alcohol of formula (VIII) B-YH (VIII) (where B and Y are as defined above). Such a reaction may, for example, be effected at room temperature in an organic solvent. Compounds of the invention in which Y represents NH may be prepared by an alternative process in which a compound of general formula (IX) (where W is as defined above) is reacted with an amine of general formula B-NH₂ (X) (where B is as defined above). This process may be performed in the absence of a solvent but is usually carried out by heating the reactants in the presence of a suitable inert organic solvent, for example toluene, pyridine, xylene, chlorobenzene, dimethylformamide or dioxan. Pyridine is the preferred solvent. Often it is convenient to reflux the reactants in the solvent. Compounds of the invention in which Y is NH may be prepared by reacting an isocyanate or isothiocyanate of formula B-NCW (XII) (where B and W are as defined above) with an amine of formula The compounds of the invention in which B represents the N-oxide of the radical (III) may be prepared by oxidising a compound in which B represents the radical (III) with, for example, hydrogen peroxide or a peracid. If in any of the above processes a reactant contains groups that would be affected under the reaction conditions employed for the reaction the group may be protected and the protecting group subsequently removed. The starting materials for the above processes are either described in the literature or may be prepared by methods known for analogous compounds. If in the processes described above the compound of the invention is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid addition salt. Conversely, if the product of the process is a free base, an acid addition salt, particularly a pharmaceutically acceptable acid addition salt may be obtained by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Examples of acid addition salts are those formed from inorganic and organic acids, such as sulphuric, hydrochloric, hydrobromic, phosphoric, tartaric, fumaric, maleic, citric, acetic, formic, methane-sulphonic, p-toluenesulphonic, oxalic and succinic acids. The compounds of the present invention possess pharmacological activity. In particular they antagonise specific 5-hydroxytryptamine (5-HT) receptors in warm blooded animals. Specifically the compounds possess 5-HT₃ antagonistic activity and hence are of value in conditions where antagonism of 5-HT₃ receptors is desirable. 5-HT₃-antagonists are also termed "antagonists of "neuronal" 5-hydroxytryptamine receptors" and "serotonin (5-hydroxytryptamine) M-receptor antagonists". Such compounds have been described as being useful inter alia in the treatment of migraine, emesis, anxiety, gastro-intestinal disorders and as anti-psychotics. The compounds of the invention are tested for 5-HT₃ antagonistic activity in the isolated right atrium of the rabbit heart based upon the method of Fozard J.R., Naunyn-Schmiedeberg's Arch. Pharmacol., 1984, 326 , 36-44. This procedure relies upon the ability of 5-HT to stimulate 5-HT₃ receptors present on sympathetic nerve terminals in the heart, causing release of noradrenaline which evokes an increase in the spontaneous rate of beating. The antagonist potency is expressed as -log IC₅₀ (where IC₅₀ is the concentration of antagonist which reduces the chronotropic response to 10⁻⁵M 5-HT by 50%). When tested by this procedure N-(1-azabicyclo[2.2.2]-octan-3-yl)-N'-(3,5-dichlorophenyl)urea a representative compound of this invention, had -log IC₅₀ of 8.3. The (S)-enantiomer of the compound had -log IC₅₀ of 9.3. The compounds of the invention are tested for potential anxiolytic activity by a test procedure measuring mouse exploratory activity in a two-compartment light/dark box based upon the procedure of B Costall et all, Neuropharmacology, 1987, 26 , 195-200 and J N Crawley et al, Pharmac. Biochem. Behav., 1980, 13 , 167-170. The test involves observing groups of mice placed in an open topped box, one third of which is painted black and illuminated under a dim red light and partitioned from the remainder of the box which is painted white and brightly illuminated. Access between the two sections is via an opening in the centre of the partition. The groups of mice are treated with vehicle or test compound and various behavioural parameters of the animals are measured including the number of exploratory rearings made by the mice in each section and the number of times the mice cross lines marked on the floor of each section. For each treatment group the mean number of line crossings and rears in each section of the box are calculated. Differences between drug-treated groups and vehicle-treated controls are compared using Student's unpaired t-test. Standard anxiotic agents significantly increase locomotion and rearing in the light section. Test compounds are considered to be active if they induce a similar set of changes and, in particular, if they produce a significant (p <0.05) increase in rearing activity in the light section of the box. Results for compounds of the invention and a standard anxiolytic agent are given below: Compound (dose mg/kg s.c.) % Change Relative to Controls Line Crossings Rears Ex.1 (0.1) + 40% + 85% Ex.5 (1.0) + 42% + 75% Ex.6 (0.1) + 69% + 90% Chlordiazepoxide (2.0) + 42% + 77% (Student's unpaired t-test relative to vehicle treated controls.) The invention further provides a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof for use in antagonising 5-HT₃ receptors in a mammal. In a further aspect the invention provides the use of a compound of the invention for the treatment of migraine, emesis, anxiety, gastro-intestinal disorders or psychotic disorders. The invention also provides a method for the treatment of migraine, emesis, anxiety, gastro-intestinal disorders or psychotic disorders which comprises administering to a warm blooded animal in need thereof, an effective amount of the compound of the invention. For certain of the above mentioned conditions it is clear that the compounds may be used prophylactically as well as for the alleviation of acute symptoms. References herein to "treatment" or the like are to be understood to include such prophylactic treatment, as well as treatment of the acute conditions. The anti-emetic properties of the compounds are particularly advantageous in the treatment of nausea and vomiting associated with cancer chemotherapeutic agents and radiation therapy. The compounds are therefore of use in the treatment of cancer by chemotherapeutic agents (cytotoxic or cytostatic agents such as cisplatin, doxorubicin and cyclophosphamide) as well as irradiation. Accordingly, the invention also provides a product containing a cancer chemotherapeutic agent and a compound of the invention as a combined preparation for simultaneous, separate or sequential use in cancer therapy. In a further aspect the invention provides a pharmaceutical composition comprising a compound of the invention in association with a pharmaceutically acceptable carrier. Any suitable carrier known in the art can be used to prepare the pharmaceutical composition. In such a composition, the carrier is generally a solid or liquid or a mixture of a solid and a liquid. Solid form compositions include powders, granules, tablets, capsules (e.g. hard and soft gelatin capsules),suppositories and pessaries. A solid carrier can be, for example, one or more substances which may also act as flavoring agents, lubricants, solubilisers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99%, e.g. from 0.03 to 99%, preferably 1 to 80% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins. The term "composition" is intended to include the formulation of an active ingredient with encapsulating material as carrier to give a capsule in which the active ingredient (with or without other carriers) is surrounded by the carrier, which is thus in association with it. Similarly cachets are included. Liquid form compositions include, for example, solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredients, for example, can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilisers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols e.g. glycerol and glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration. Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. When the compound is orally active it can be administered orally either in liquid or solid composition form. The compounds of the invention can also be administered by the nasal route. When formulated for nasal administration the compositions may comprise a compound of the invention in liquid carrier; such compositions may be administered for example in the form of a spray or as drops. The liquid carrier may be water (which may contain further components to provide the desired isotonicity and viscosity of the composition). The composition may also contain additional excipients such as preservatives, surface active agents and the like. The compositions may be contained in a nasal applicator that enables the composition to be administered as drugs or as a spray. For administration from an aerosol container the composition should also include a propellant. Preferably the pharmaceutical composition is in unit dosage form, eg as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged composition, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. The quantity of the active ingredient in unit dose of composition may be varied or adjusted from 0.5 mg or less to 750 mg or more according to the particular need and the activity of the active ingredient. The invention also includes the compounds in the absence of the carrier where the compounds are in unit dosage form. The following Examples illustrate the invention. EXAMPLE 1 N-(1-azabicyclo[2.2.2]octan-3-yl-N'-(3,5-dichlorophenyl)urea A solution of 3,5-dichlorophenyl isocyanate (1.88 g, 10 mmol) in toluene (20 ml) was added at 0° to 1-azabicyclo[2.2.2]octan-3-amine (3-aminoquinuclidine) (1.26 g, 10 mmol) in THF (40 ml). The mixture was stirred at room temperature overnight and evaporated to dryness. The residue was partitioned between ether and dilute hydrochloric acid. The aqueous phase was basified with potassium carbonate and extracted with ethyl acetate. The dried (Na₂SO₄)ethyl acetate phase was evaporated and the residue (1.64 g) converted to the 1:1 oxalate, quarter hydrate, mp 208-209 °C (dec). EXAMPLE 2 N-(3,5-dichlorophenyl)-N'-(1,2-diethylpyrazolidin-4-yl)urea. A solution of 4-amino-1,2-diethylpyrazolidine (1.26 g, 8.8 mmol) in anhydrous toluene (5 ml) was added to a solution of 3,5-dichlorophenyl isocyanate (1.71 g, 9.1 mmol) in dry toluene (20 ml) and the mixture stirred overnight. The precipitated solid was collected, washed with toluene and dried to give the title compound, 1.94 g. This was converted to the 1:1 maleate, mp 165-167 °C. EXAMPLE 3 N-(Azabicyclo[2.2.2]octan-3-yl)-N'-(3,5-dichlorophenyl)thiourea Thiophosgene (1.0 ml, 1.51 g, 13.13 mmol) was suspended in water (10 ml) and stirred vigorously while 3,5-dichloroaniline (1.62 g, 10 mmol) in chloroform (8 ml) was added over 1 min. Triethylamine (1.4 g, 13.86 mmol) was added and stirring was continued for 30 min. The aqueous phase was discarded and the chloroform retained. 3-Aminoquinuclidine dihydrochloride (1.99 g, 10 mmol) was dissolved in water (2 ml) and treated with sodium hydroxide pellets until the pH was 9. This solution was then added to the above chloroform solution and the two stirred together overnight. The aqueous phase was extracted 3 times with chloroform. The combined organic phases were washed once with water. An insoluble oil was separated. The chloroform solution was dried (Na₂S0₄) and evaporated, and the residue combined with the insoluble oil. This material was triturated with dichloromethane for 3 h to give the title product, 2.09 g, mp 137-140 °C, as hydrochloride containing 0.5 mole of dichloromethane not removable by drying. EXAMPLE 4 Endo-N-(3,5-dichlorophenyl)-N'-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)urea The above compound was prepared, following the procedure of Example 1, from 3,5-dichlorophenylisocyanate (0.94 g, 5 mmol) and (endo)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine (3-aminotropane) (0.70 g, 5 mmol). The product was isolated as the 1:1 maleate (0.58 g), mp 208-210 °C. EXAMPLE 5 (S)-(-)-N-(1-Azabicyclo[2.2.2]octan-3-yl)-N'-(3,5-dichlorophenyl)urea (a) (3S)-3-[(S)-α-methylbenzylamino]quinuclidine A mixture of 3-quinuclidinone hydrochloride (80.5 g, 0.5 mol), (S)-α-methylbenzylamine (180 g, 1.49 mol), sodium cyanoborohydride (31g, 0.5 mol). 3Å molecular sieve (75 g), methanol (750 ml), and enough gaseous hydrogen chloride to give a pH of approx 6 was stirred in ice for 1 h, then at room temperature overnight, with addition of hydrogen chloride as necessary to maintain pH 6. The mixture was filtered and the filtrate evaporated. The residue was dissolved in water, basified with potassium hydroxide, and extracted with ethyl acetate. The ethyl acetate extracts were dried (Na₂SO₄), evaporated and distilled. The product fraction, bp 138-142° C (2 mbar) was fractionally crystallised as its hydrochloride to give the title compound (29.22 g), mp 238-242° C (phase change 193-200° C). (b) (S)-(-)-3-aminoquinuclidine (3S)-3-[(S)-α-methylbenzylamino]quinuclidine hydrochloride (24.38 g, 91.5 mmol) in water (80 ml) and glacial acetic acid (130 ml) was hydrogenated over 10% Pd/C (1.2 g) at 50 °C and 40 psi (about 2.7 x 10⁵ Pa). The mixture was filtered, the filtrate treated with concentrated hydrochloric acid (10 ml) and evaporated. The residue was triturated with isopropanol to give the title compound dihydrochloride (16.6 g). A second crop (0.5 g) of dihydrobromide salt, mp 273-280 °C (phase change >240 °C) [α] 25 / D = -16°(C=1, H₂0) was obtained from the isopropanol mother-liquors by treating with excess hydrogen bromide and concentrating to low volume until crystallisation occurred. (c) (S)-(-)-N-(1-Azabicyclo[2.2.2]octan-3-yl)-N'-(3,5-dichlorophenyl)urea The above compound was prepared, following the procedure of Example 1, from (S)-3-aminoquinuclidine (1.98 g, 15.71 mmol) and 3,5-dichlorophenyl isocyanate (2.96 g, 15.74 mmol) to give the title compound (0.95 g), mp 200-201 °C, [α] 26 / D = -21° (C=1, CHCl₃). EXAMPLE 6 (R)-(+)-N-(1-Azabicyclo[2.2.2]octan-3-yl) -N'-(3,5-dichlorophenyl)urea (a) (3R)-3-[(S)-α-methylbenzylamino]quinuclidine The above compound was obtained from the mother-liquors of the (3S)-3-[(S)-α-methylbenzylamino]quinuclidine hydrochloride, the preparation of which is given in example 5a, by fractional crystallisation as the 1:1 di-p-toluoyl-L-tartrate (44.8 g), mp 172-174 °C. (b) (R)-(+)-3-aminoquinuclidine (3R)-3-[(S)-α-methylbenzylamino]quinuclidine di-p-toluoyl-L-tartrate (39.7 g, 62.6 mmol) was partitioned between ether (200 ml) and 5 M aqueous potassium hydroxide (50 ml). The aqueous phase was extracted again with ether, the combined ethereal phases dried (Na₂SO₄) and evaporated. The residue was hydrogenated in glacial acetic acid (130 ml) over 10% Pd/C (1.1 g) at 50 °C and 45 psi (about 3.1 x 10⁵ Pa). The mixture was worked-up as in example 5b to give the title compound dihydrochloride (10.1 g), [α] 25 / D = +16.5 (C=1, H₂O) with a second crop of dihydrobromide (0.5 g), mp 284-285 °C (phase change >230 °C). (c) (R)-(+)-N-(1-Azabicyclo[2.2.2]octan-3-yl)-N-(3,5-dichlorophenyl)urea The above compound was prepared, following the procedure of Example 1, from (R)-3-aminoquinuclidine (1.26 g, 10 mmol) and 3,5-dichlorophenyl isocyanate (1.88 g, 10 mmol) to give the title compound quarter hydrate (1.35 g), mp 190-194 °C (forms a gum at 180-183 °C), [α]²³ = +23° (C=1, CHCl₃). EXAMPLE 7 (Endo)-O-[8-Methyl-8-azabicyclo[3.2.1]octan-3-yl]-N-(3,5-dichlorophenyl)carbamate Tropine (1.0 g, 7.04 mmol) was added to 3,5-dichlorophenyl isocyanate (1.32 g, 7.02 mmol) in dichloromethane (20 ml) at room temperature under nitrogen. The reaction mixture was stirred for 20 h, the solid collected and partitioned between ether and dilute hydrochloric acid. The insoluble solid was collected and washed with dilute hydrochloric acid then ether to give the above compound as its hydrochloride (0.73 g), mp 288-294 °C (dec).

Claims: Claims for the following Contracting States : AT, BE, CH, DE, FR, IT, LI, LU, NL, SE A heterocyclic compound of the general formula or a pharmaceutically acceptable acid addition salt thereof where W represents oxygen or sulphur, Y represents NH or O, B represents a saturated azacyclic ring of the formula where n is 2,3 or 4 and R³ is hydrogen, or (lower)alkyl, or or the N-oxide thereof or where m is 1, 2 or 3 and R³ has the meaning given above or where p is 0, 1 or 2 or where R⁴ and R⁵ are each hydrogen or lower alkyl and wherein the term "lower" means that the radical referred to contains up to 6 carbon atoms. A compound as claimed in claim 1 wherein B is tropan-3-yl or quinuclidin-3-yl. N-(1-Azabicyclo[2.2.2]octan-3-yl)-N'-(3,5-dichlorophenyl)urea or a pharmaceutically acceptable salt thereof. N-(3,5-Dichlorophenyl)-N'-(1,2-diethylpyrazolidin-4-yl)urea, N-(azabicyclo[2.2.2]octan-3-yl-N'-(3,5-dichlorophenyl)thiourea, (endo)-N-(3,5-dichlorophenyl)-N'-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)urea, (S)-(-)-N-(1-azabicyclo[2.2.2]octan-3-yl)-N'-(3,5-dichlorophenyl)urea, (R)-(+)-N-(1-azabicyclo[2.2.2]octan-3-yl)-N'-(3,5-dichlorophenyl)urea or (endo-O-[8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-N-(3,5-dichlorophenyl)carbamate, or a pharmaceutically acceptable salt thereof. A process for preparing a compound as claimed in claim 1 which comprises (a) reacting an isocyanate or isothiocyanate of formula (VII) (where W is as defined in claim 1) with an amine or alcohol of formula (VIII) B-YH (VIII) (where B and Y are as defined in claim 1) or (b) reacting a compound of general formula (IX) (where W is as defined in claim 1) with an amine of general formula B-NH₂ (X) (where B is as defined in claim 1) to give a compound of formula (I) in which Y represents NH or (c) reacting an isocyanate or isothiocyanate of formula B-NCW (XII) (where B and W are as defined in claim 1) with an amine of formula to give a compound of formula (I) in which Y is NH or (d) oxidising a compound of formula (I) in which B represents the radical (III) to give a compound of formula (I) in which B represents the N-oxide of the radical (III) or (e) converting a base of formula (I) into a pharmaceutically acceptable acid addition salt thereof, or (f) resolving a racemic compound of formula (I) into an optical isomer thereof. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 5 in association with a pharmaceutically acceptable carrier. A pharmaceutical composition as claimed in claim 6 in the form of a spray or as drops for nasal administration. A product containing a compound as claimed in any one of claims 1 to 4 and a cancer chemotherapeutic agent as a combined preparation for simultaneous, separate or sequential use in cancer therapy. A compound as claimed in any one of claims 1 to 5 for use as a pharmaceutical. Claims for the following Contracting States : ES, GR A process for preparing a heterocyclic compound of the general formula or a pharmaceutically acceptable acid addition salt thereof where W represents oxygen or sulphur, Y represents NH or O, B represents a saturated azacyclic ring of the formula where n is 2,3 or 4 and R³ is hydrogen, or (lower)alkyl, or or the N-oxide thereof or where m is 1, 2 or 3 and R³ has the meaning given above or where p is 0, 1 or 2 or where R⁴ and R⁵ are each hydrogen or lower alkyl and wherein the term "lower" means that the radical referred to contains up to 6 carbon atoms which comprises (a) reacting an isocyanate or isothiocyanate of formula (VII) (where W is as defined above) with an amine or alcohol of formula (VIII) B-YH (VIII) (where B and Y are as defined in above) or (b) reacting a compound of general formula (IX) (where W is as defined above) with an amine of general formula B-NH₂ (X) (where B is as defined above) to give a compound of formula (I) in which Y represents NH or (c) reacting an isocyanate or isothiocyanate of formula B-NCW (XII) (where B and W are as defined above) with an amine of formula to give a compound of formula (I) in which Y is NH or (d) oxidising a compound of formula (I) in which B represents the radical (III) to give a compound of formula (I) in which B represents the N-oxide of the radical (III) or (e) converting a base of formula (I) into a pharmaceutically acceptable acid addition salt thereof, or (f) resolving a racemic compound of formula (I) into an optical isomer thereof. A process as claimed in claim 1 wherein B in the product is tropan-3-yl or quinuclidin-3-yl. A process as claimed in claim 1 wherein the product is N-(1-azabicyclo[2.2.2]octan-3-yl)-N'-(3,5-dichlorophenyl)urea or a pharmaceutically acceptable salt thereof. A process as claimed in claim 1 wherein the product is N-(3,5-dichlorophenyl)-N'-(1,2-diethylpyrazolidin-4-yl)urea, N-(azabicyclo[2.2.2]octan-3-yl-N'-(3,5-dichlorophenyl)thiourea, (endo)-N-(3,5-dichlorophenyl)-N'-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)urea, (S)-(-)-N-(1-azabicyclo[2.2.2]octan-3-yl)-N'-(3,5-dichlorophenyl)urea, (R)-(+)-N-(1-azabicyclo[2.2.2]octan-3-yl)-N'-(3,5-dichlorophenyl)urea or (endo-O-[8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-N-(3,5-dichlorophenyl)carbamate, or a pharmaceutically acceptable salt thereof. A process for preparing a pharmaceutical composition which comprises bringing a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable acid addition salt thereof into association with a pharmaceutically acceptable carrier. A process as claimed in claim 5 for preparing a pharmaceutical composition in the form of a tablet or capsule for oral administration or in the form of a spray or as drops for nasal administration. A process as claimed in claim 5 in which a cancer chemotherapeutic agent is additionally incorporated into the composition. A process as claimed in any one of claims 5 to 7 in which the compound of formula (I) or its salt is prepared by the process claimed in any one of claims 1 to 4.

Inventors: WARD TERENCE JAMES, WHITE JANET CHRISTINE, WARD, TERENCE JAMES, WHITE, JANET CHRISTINE
Applicants: WYETH JOHN & BROTHER LTD, JOHN WYETH & BROTHER LIMITED
Application year: 1988
Main classification: C07D451
IPC codes: C07D231, C07D451, C07D453